Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Agenus Inc.
  6. News
  7. Summary
    AGEN   US00847G7051


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agenus Inc. Announces the U.S. Food and Drug Administration Clearance of an Investigational New Drug Application for Therapy, AGEN1777

07/06/2021 | 08:30am EDT

Agenus Inc. announced the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for this therapy. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. Bristol Myers Squibb intends to advance the research and development of AGEN1777 in immuno-oncology for high priority tumor indications including non-small cell lung cancer. Phase 1 dosing for AGEN1777 is expected to begin during the third quarter of 2021. This dose escalation study is designed to evaluate the safety, tolerability, and preliminary clinical activity of AGEN1777 as a single agent and in combination with a PD-1 inhibitor in patients with advanced solid tumors. Under the terms of the agreement with Bristol Myers Squibb, Agenus receives a $200 million upfront payment in connection with the closing. The agreement also includes up to $1.36 billion in development, regulatory and commercial milestones in addition to tiered double-digit royalties on net product sales. Bristol Myers Squibb will become solely responsible for the development and any subsequent commercialization of AGEN1777 and its related products worldwide. Agenus will retain options to conduct clinical studies under the development plan, to conduct combination studies with certain other Agenus pipeline assets, and also, upon commercialization, to co-promote AGEN1777 in the US. AGEN1777 is a potentially first-in-class bispecific anti-TIGIT antibody engineered with an enhanced Fc region for high binding affinity and improved T and NK cell activation.

ę S&P Capital IQ 2021
All news about AGENUS INC.
09/17AGENUS : ESMO 2021 - Agenus Presents Updates on Balstilimab Plus Zalifrelimab Combination
09/17ABCELLERA BIOLOGICS : Health Care Stocks Down to End Week
09/17Health Care Stocks Mixed Premarket Friday
09/17AGENUS : Says Cervical Cancer Combination Therapy Shows 'High' Response Rates in Phase 2 T..
09/16Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in..
09/14INSIDER SELL : Agenus
09/10AGENUS : New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Co..
09/10Agenus Inc. Announces New Subsidiary, SaponiQx
09/09AGENUS : to Participate in September Investor Conferences
09/07AGENUS : B. Riley Raises Agenus' PT to $12 from $11, Says Continued Regulatory Progress to..
More news
Analyst Recommendations on AGENUS INC.
More recommendations
Financials (USD)
Sales 2021 263 M - -
Net income 2021 -95,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -13,4x
Yield 2021 -
Capitalization 1 375 M 1 375 M -
Capi. / Sales 2021 5,22x
Capi. / Sales 2022 13,9x
Nbr of Employees 359
Free-Float 87,2%
Duration : Period :
Agenus Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGENUS INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Last Close Price 5,90 $
Average target price 10,00 $
Spread / Average Target 69,5%
EPS Revisions
Managers and Directors
Garo H. Armen Chairman & Chief Executive Officer
Jennifer S. Buell President & Chief Operating Officer
Christine M. Klaskin Chief Financial & Accounting Officer, VP-Finance
Marc van Dijk Chief Technology Officer
Steven OĺDay Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AGENUS INC.85.53%1 375
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
CELLTRION, INC.-25.49%31 745
SEAGEN INC.-7.88%29 353